The clinical pharmacology of the oral fluoropyrimidines
- 1 June 2001
- journal article
- review article
- Published by Elsevier in Current Problems in Cancer
- Vol. 25 (3) , 134-213
- https://doi.org/10.1067/mcn.2001.116058
Abstract
No abstract availableThis publication has 171 references indexed in Scilit:
- Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeHead & Neck, 1997
- Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II studyEuropean Journal Of Cancer, 1995
- Phase II study of oral ftorafur and uracil in patients with advanced renal cell carcinomaEuropean Journal Of Cancer, 1993
- Synergism and Lack of Cross-resistance Between Short-term and Continuous Exposure to Fluorouracil in Human Colon Adenocarcinoma CellsJNCI Journal of the National Cancer Institute, 1993
- A dose-intensive regimen of 5-fluorouracil for the treatment of metastatic colorectal carcinomaCancer, 1991
- A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. A mid-atlantic oncology program studyCancer, 1991
- Tolerance of Extended (28 Day) Continuous Infusion of 5-Fluorouracil in Advanced Head and Neck CancerSelective Cancer Therapeutics, 1991
- Clinical Pharmacology of 5-FluorouracilClinical Pharmacokinetics, 1989
- Familial Pyrimidinemia and Pyrimidinuria Associated with Severe Fluorouracil ToxicityNew England Journal of Medicine, 1985
- Fluorinated Pyrimidines, A New Class of Tumour-Inhibitory CompoundsNature, 1957